0000899243-22-024385.txt : 20220628
0000899243-22-024385.hdr.sgml : 20220628
20220628160520
ACCESSION NUMBER: 0000899243-22-024385
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220624
FILED AS OF DATE: 20220628
DATE AS OF CHANGE: 20220628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kewalramani Reshma
CENTRAL INDEX KEY: 0001735944
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 221050104
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-24
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001735944
Kewalramani Reshma
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
CEO & President
Common Stock
2022-06-24
4
S
0
11689
291.30
D
111153
D
Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $291.30 (range $291.00 to $291.49).
/s/ Sabrina Yohai, Attorney-in-Fact
2022-06-28